| Authors: |
Rabinowits G; 1Department of Hematology and Oncology, Miami Cancer Institute/Baptist Health South Florida, Miami, FL., Park SJ; 2Department of Medicine, Division of Hematology and Oncology, University of California San Diego, La Jolla, CA; NIK., Khushalani NI; 3Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL., Panella T; 4Division of Hematology and Oncology, University of Tennessee Medical Center, Knoxville, TN., Ellison DM; 5Charleston Oncology, Charleston, SC., Gentry RW; 6CARTI Cancer Center, Little Rock, AR., Venna SS; 7Inova Schar Cancer Institute Melanoma Center, Fairfax, VA., Strasswimmer J; 8Florida Atlantic University College of Medicine, Boca Raton, FL., Zuniga RM; 9New York Cancer and Blood Specialists, Babylon, NY., Chandra S; 10Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Ruiz ES; 11Department of Dermatology, Brigham and Women's Hospital, Boston, MA., Migden MR; 12Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., Ibrahim SF; 13Rochester Dermatologic Surgery, PC, Victor, NY., Yan E; 14Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Zhu C; 14Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Pouliot JF; 14Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Quek RGW; 14Regeneron Pharmaceuticals, Inc., Tarrytown, NY. |
